Hints and tips:
Related Special Reports
...,” said Hannah White, director of the Institute for Government think-tank....
...Chief executive Peggy Johnson, who oversaw the release of Magic Leap 2 last September, alluded in a recent company blog post to a new revenue stream, saying it has “received an incredible amount of interest...
...Peter Johnson, NHS England national clinical director for cancer, said there was “very low risk to the NHS in an undertaking like this compared to the very big risk the company is taking on”....
...Johnson & Johnson has raised its forecasts for the full year after it beat expectations on earnings and revenue, partly driven by soaring sales of cancer drugs in the US....
...For Ayanna Witter-Johnson, a student gig singing at a Caribbean restaurant in London shaped her entire career....
...Hannah Kuchler is the FT’s global pharmaceutical editor Follow @FTMag to find out about our latest stories first...
...Hannah?...
...CMR Surgical’s former chief executive Per Vegard Nerseth last year warned then UK prime minister Boris Johnson that the UK would lose out on manufacturing investment if it failed to offer more incentives...
...Horizon had also attracted interest from French drugmaker Sanofi and US pharma group Johnson & Johnson....
...In 2020, Pfizer spun off its generics business Upjohn, combining it with Mylan to form Viatris, while Johnson & Johnson, GSK, Pfizer and Novartis have all shed their consumer health businesses selling over-the-counter...
...Other drugmakers including Merck, Bristol Myers Squibb, and Johnson & Johnson, as well as the US pharmaceutical lobby group, have already filed lawsuits against the reforms....
...The writer is director of the Institute for Government, a think-tank The resignation honours lists in which Boris Johnson and Liz Truss rewarded their acolytes emerged over the summer as just the latest...
...Cancer, stroke and diabetes medications made by Merck, Johnson & Johnson and Bristol Myers Squibb are among the first tranche of medications selected for negotiation....
...Over the past 12 months Lilly’s shares have increased by 75 per cent, enabling the Indianapolis-based company to surpass Johnson & Johnson as the world’s most valuable drugmaker by market capitalisation....
...Earlier this month, Johnson & Johnson and Japanese drugmaker Astellas Pharma filed lawsuits against the Biden administration’s reforms, following on from legal challenges filed by Merck, Bristol Myers Squibb...
...Pharmaceutical companies including AstraZeneca and Johnson and Johnson already work with the UK Biobank to access genomic data....
...Miles Johnson investigates a mysterious murder in a small town that leads to a web of drugs, money laundering and state-sponsored assassinations stretching from Dublin to Dubai....
...The Baillie Gifford prize for non-fiction was founded in 1999 and originally named after the 18th-century author and lexicographer Samuel Johnson....
...He has an iconoclastic take on revered figures, such as Isaiah Berlin, Karl Popper and Hannah Arendt....
...The former chief scientific officer of Johnson & Johnson is on the hunt for acquisitions after he took the reins at the struggling Belgian biotech Galapagos this year....
...Johnson & Johnson maintained its adjusted full-year guidance after beating earnings expectations in the third quarter, despite a strong dollar weighing down on sales outside the US....
...The tone was set by Boris Johnson’s refusal to dismiss Priti Patel from cabinet after his own ethics adviser found she had bullied her civil servants....
...Rachman Review — FT journalist Miles Johnson explains the shadowy links between rouge states like North Korea and the criminal underworld....
...Recently, the US regulator has shown it is open to considering versions of drugs better-known for their recreational properties, approving Johnson & Johnson’s drug based on ketamine for treatment-resistant...
International Edition